Compare Essex Property Trust, Inc. (ESS) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Essex Property Trust, Inc. vs Novo Nordisk A/S — how do they compare? Essex Property Trust, Inc. trades at $298.43 (market cap $18.82B), while Novo Nordisk A/S trades at $51.58 (market cap $222.24B). The key difference: Novo Nordisk A/S is far larger — about 11.8× Essex Property Trust, Inc.'s market cap, and Novo Nordisk A/S pays the higher dividend (3.56%). Which is the better fit depends on your goals.
| ESS | NVO | |
|---|---|---|
Market Cap | $18.82B | $222.24B |
Sector | Real Estate | Health |
52-Week High | $298.33 | $71.70 |
52-Week Low | $239.61 | $35.29 |
Enterprise Value | $25.54B | $241.20B |
Dividend Yield | 3.54% | 3.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Essex Property Trust (ESS) trades at $293.32, down 1.61% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong profitability with a 30.03% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights include the upcoming Q2 2026 earnings release and inclusion in the Russell Microcap Index, reflecting positive momentum.
The outlook for ESS is cautiously optimistic, driven by robust West Coast rental demand and AI-driven employment growth. Risks include elevated debt levels and Seattle market weakness. Analysts maintain a mixed consensus with a $294.25 price target, suggesting limited near-term upside from current levels amid balanced sentiment.
Novo Nordisk (NVO) trades at $49.07, down 0.43% on the day, amid a bullish technical signal and strong fundamental performance. The stock exhibits robust profitability with a 37.2% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights EU approval for its Wegovy weight-loss pill, reinforcing its competitive position in the GLP-1 market.
The outlook remains positive given earnings momentum and expanding product approvals, though risks include rising competition from generics and potential prescription slowdowns. Analyst consensus is bullish with 57.9% buy ratings, supporting a favorable risk-reward profile for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
